Nortriptyline Hydrochloride Solubility-pH Profiles in a Saline Phosphate Buffer: Drug-Phosphate Complexes and Multiple pHmax Domains with a Gibbs Phase Rule “Soft” Constraints
Article (Accepted Version)
Metadata
Show full item recordAbstract
The solubility of a model basic drug, nortriptyline (Nor), was investigated as a function of pH in phosphate and/or a chloride-containing aqueous suspension using experimental practices recommended in the previously published “white paper” (Avdeef et al., 2016). The pH-Ramp Shake-Flask (pHRSF) method, introduced in our earlier work (Marković et al.,2019), was applied. An improved and more detailed experimentaldesign of the Nor solubility measurement allowed us to exploit thefull capacity of the pH-RSF method. Complex equilibria in theaqueous phase (cationic and anionic complex formation betweenNor and the phosphate) and solid-phase transformations (Nor freebase, 1:1 Nor hydrochloride salt, 1:1 and 1:2 Nor phosphate salts)were characterized by a detailed analysis of the solubilitymeasurements using the computer program pDISOL-X. The solid phases were characterized by thermogravimetric analysis,differential scanning calorimetry, powder X-ray diffraction, and elemental analyses. The resu...lts of the present investigation illustratethe influence of competing counterions, such as buffering agents, complexing agents, salt coformers, tonicity adjusters, and so forth,on the aqueous solubility of drugs and interconversion of salts. Careful attention given to these factors can be helpful in theformulation of drug products.
Keywords:
nortriptyline / nortriptyline hydrochloride / phosphate salts / complexes / solubility / solubility product / pH and buffer effectSource:
Molecular Pharmaceutics, 2022, 19, 2, 710-719Publisher:
- American Chemical Society (ACS)
Funding / projects:
- Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 200026 (University of Belgrade, Institute of Chemistry, Technology and Metallurgy - IChTM) (RS-200026)
- Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 200168 (University of Belgrade, Faculty of Chemistry) (RS-200168)
Note:
- This is the peer-reviewed version of the article: Marković, Olivera S., Patel, Nirali G., Serajuddin, Abu T. M., Avdeef, Alex, Verbić, Tatjana Ž., "Nortriptyline Hydrochloride Solubility-pH Profiles in a Saline Phosphate Buffer: Drug-Phosphate Complexes and Multiple pHmax Domains with a Gibbs Phase Rule “Soft” Constraints", Molecular Pharmaceutics, 19, no. 2 (2022):710-719, https://doi.org/10.1021/acs.molpharmaceut.1c00919
- This document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.molpharmaceut.1c00919
- The published version: https://cer.ihtm.bg.ac.rs/handle/123456789/4934
- Supporting information: https://cer.ihtm.bg.ac.rs/handle/123456789/4935
Related info:
- Version of
https://cer.ihtm.bg.ac.rs/handle/123456789/4934 - Version of
https://doi.org/10.1021/acs.molpharmaceut.1c00919 - Referenced by
https://cer.ihtm.bg.ac.rs/handle/123456789/4935
DOI: 10.1021/acs.molpharmaceut.1c00919
ISSN: 1543-8384
PubMed: 35050628
WoS: 000746418500001
[ Google Scholar ]Collections
Institution/Community
IHTMTY - JOUR AU - Marković, Olivera AU - Patel, Nirali G. AU - Serajuddin, Abu T. M. AU - Avdeef, Alex AU - Verbić, Tatjana PY - 2022 UR - https://cer.ihtm.bg.ac.rs/handle/123456789/4936 AB - The solubility of a model basic drug, nortriptyline (Nor), was investigated as a function of pH in phosphate and/or a chloride-containing aqueous suspension using experimental practices recommended in the previously published “white paper” (Avdeef et al., 2016). The pH-Ramp Shake-Flask (pHRSF) method, introduced in our earlier work (Marković et al.,2019), was applied. An improved and more detailed experimentaldesign of the Nor solubility measurement allowed us to exploit thefull capacity of the pH-RSF method. Complex equilibria in theaqueous phase (cationic and anionic complex formation betweenNor and the phosphate) and solid-phase transformations (Nor freebase, 1:1 Nor hydrochloride salt, 1:1 and 1:2 Nor phosphate salts)were characterized by a detailed analysis of the solubilitymeasurements using the computer program pDISOL-X. The solid phases were characterized by thermogravimetric analysis,differential scanning calorimetry, powder X-ray diffraction, and elemental analyses. The results of the present investigation illustratethe influence of competing counterions, such as buffering agents, complexing agents, salt coformers, tonicity adjusters, and so forth,on the aqueous solubility of drugs and interconversion of salts. Careful attention given to these factors can be helpful in theformulation of drug products. PB - American Chemical Society (ACS) T2 - Molecular Pharmaceutics T1 - Nortriptyline Hydrochloride Solubility-pH Profiles in a Saline Phosphate Buffer: Drug-Phosphate Complexes and Multiple pHmax Domains with a Gibbs Phase Rule “Soft” Constraints VL - 19 IS - 2 SP - 710 EP - 719 DO - 10.1021/acs.molpharmaceut.1c00919 ER -
@article{ author = "Marković, Olivera and Patel, Nirali G. and Serajuddin, Abu T. M. and Avdeef, Alex and Verbić, Tatjana", year = "2022", abstract = "The solubility of a model basic drug, nortriptyline (Nor), was investigated as a function of pH in phosphate and/or a chloride-containing aqueous suspension using experimental practices recommended in the previously published “white paper” (Avdeef et al., 2016). The pH-Ramp Shake-Flask (pHRSF) method, introduced in our earlier work (Marković et al.,2019), was applied. An improved and more detailed experimentaldesign of the Nor solubility measurement allowed us to exploit thefull capacity of the pH-RSF method. Complex equilibria in theaqueous phase (cationic and anionic complex formation betweenNor and the phosphate) and solid-phase transformations (Nor freebase, 1:1 Nor hydrochloride salt, 1:1 and 1:2 Nor phosphate salts)were characterized by a detailed analysis of the solubilitymeasurements using the computer program pDISOL-X. The solid phases were characterized by thermogravimetric analysis,differential scanning calorimetry, powder X-ray diffraction, and elemental analyses. The results of the present investigation illustratethe influence of competing counterions, such as buffering agents, complexing agents, salt coformers, tonicity adjusters, and so forth,on the aqueous solubility of drugs and interconversion of salts. Careful attention given to these factors can be helpful in theformulation of drug products.", publisher = "American Chemical Society (ACS)", journal = "Molecular Pharmaceutics", title = "Nortriptyline Hydrochloride Solubility-pH Profiles in a Saline Phosphate Buffer: Drug-Phosphate Complexes and Multiple pHmax Domains with a Gibbs Phase Rule “Soft” Constraints", volume = "19", number = "2", pages = "710-719", doi = "10.1021/acs.molpharmaceut.1c00919" }
Marković, O., Patel, N. G., Serajuddin, A. T. M., Avdeef, A.,& Verbić, T.. (2022). Nortriptyline Hydrochloride Solubility-pH Profiles in a Saline Phosphate Buffer: Drug-Phosphate Complexes and Multiple pHmax Domains with a Gibbs Phase Rule “Soft” Constraints. in Molecular Pharmaceutics American Chemical Society (ACS)., 19(2), 710-719. https://doi.org/10.1021/acs.molpharmaceut.1c00919
Marković O, Patel NG, Serajuddin ATM, Avdeef A, Verbić T. Nortriptyline Hydrochloride Solubility-pH Profiles in a Saline Phosphate Buffer: Drug-Phosphate Complexes and Multiple pHmax Domains with a Gibbs Phase Rule “Soft” Constraints. in Molecular Pharmaceutics. 2022;19(2):710-719. doi:10.1021/acs.molpharmaceut.1c00919 .
Marković, Olivera, Patel, Nirali G., Serajuddin, Abu T. M., Avdeef, Alex, Verbić, Tatjana, "Nortriptyline Hydrochloride Solubility-pH Profiles in a Saline Phosphate Buffer: Drug-Phosphate Complexes and Multiple pHmax Domains with a Gibbs Phase Rule “Soft” Constraints" in Molecular Pharmaceutics, 19, no. 2 (2022):710-719, https://doi.org/10.1021/acs.molpharmaceut.1c00919 . .